Tests exercise and atorvastatin during treatment for advanced cancers
Tests group exercise, with or without atorvastatin, in adults with advanced cancer.
Key facts
- Who runs it
- Pirkanmaan hyvinvointialue
- Where
- Tampere, FinlandSee the site
- Registry title
- Measuring Oncological Value of Exercise and Statin (MOVES)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 240 people, planned
- Started
- 31 Mar 2023
- Expected to end
- 31 Dec 2031
- Type of study
- Interventional
- Record updated
- 21 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic prostate, breast, ovarian or kidney cancer who are about to start their first anticancer treatment. It studies exercise, with or without atorvastatin.
- Age
- 18 years or older
- Sex
- Men and women can join. Breast and ovarian cancer: women. Prostate cancer: men. Kidney cancer: women and men.
- Disease stage
- Metastatic prostate, breast, ovarian or kidney cancer, confirmed by tissue examination and imaging.
- Earlier treatment
- 1st line anticancer therapy is being started. Patients not on statins at the start cannot be taking cholesterol-lowering drugs.
Main reasons for not taking part
- High fracture risk
- Unable to exercise and/or unable to receive anticancer therapy
- Severe liver or kidney failure
- Pregnant or breastfeeding women, and minors
- Not on statins at the start: current cholesterol-lowering drugs, serious side effects from them in the past, or drugs that interact with atorvastatin
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients with histologically and imaging confirmed metastatic prostate, breast, ovarian or renal cancer for which 1st line anticancer therapy is being initiated. 2) The patient consents to the study and signs a written informed consent. 3) Women (breast, ovarian and renal cancer) and men (prostate and renal cancer) of legal age (18 years =>) are recruited. 4) Women will use a reliable method of contraception during the trial
Who cannot take part
- All patients: 1. High fracture risk 2. Unable to exercise and/or unable to receive anticancer therapy 3. Psychologically uncooperative 4. Severe liver or kidney failure 5. Special category of subjects under the Medical Research Act (1999/488) (e.g. minors and pregnant or breastfeeding women). In addition to excl. criteria for patients who were not on statin medication at the start of the study: Active use of cholesterol-lowering drugs, A history of serious side effects from cholesterol-lowering drugs and Continued use of drugs that interact with atorvastatin during the period of the study
Where in Finland
- Pirkanmaan hyvinvointialueTampere, FinlandTaking people
About the trial
What the trial wants to find out
1) Whether supervised group exercise with aerobic and resistance training during anticancer therapy improves the efficacy of anticancer therapy in advanced breast, renal, ovarian, and prostate cancer compared with self-administered exercise and whether the use of atorvastatin combined with supervised group exercise further improves the response to cancer treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Measuring Oncological Value of Exercise and Statin (MOVES)
- Plain-language title
- Tests exercise and atorvastatin during treatment for advanced cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 21 May 2026